Last reviewed · How we verify

ACE-031 — Competitive Intelligence Brief

ACE-031 (ACE-031) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Myostatin inhibitor. Area: Oncology.

phase 1 Myostatin inhibitor Activin receptor type II-A (ActRIIA) Oncology Biologic Live · refreshed every 30 min

Target snapshot

ACE-031 (ACE-031) — Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA. Activates the activin receptor type II-A (ActRIIA), leading to increased myostatin inhibition.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ACE-031 TARGET ACE-031 Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA phase 1 Myostatin inhibitor Activin receptor type II-A (ActRIIA)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Myostatin inhibitor class)

  1. Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ACE-031 — Competitive Intelligence Brief. https://druglandscape.com/ci/ace-031. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: